Tag: pathways

LanzaTech JV Successful IPO Underscores Strategic Value of More Secure Fuel Supply

SKOKIE, Ill., June 04, 2026 (GLOBE NEWSWIRE) -- LanzaTech Global, Inc. (NASDAQ: LNZA) (“LanzaTech” or the “Company”), a carbon management solutions company, announced that Beijing Shougang LanzaTech Technology Co., Ltd., (the “JV”), a joint venture in which LanzaTech held a 9.31% equity stake prior to the offering described below, has launched its Initial Public Offering (IPO) of 40 million H-Shares at a public offering price equivalent to approximately US$1.86 per share, based on applicable exchange rates, on the Hong Kong Stock Exchange. The offering raised gross proceeds of approximately US$75M before underwriting discounts and commissions.

HotSpot Therapeutics Presents Preclinical Data from Small Molecule IRF5 Inhibitor Program at EULAR 2026

BOSTON, June 4, 2026 /PRNewswire/ -- HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, allosteric small molecules that target...

LIGHT AI ANNOUNCES INITIATION OF FDA PIVOTAL CLINICAL TRIAL FOR QUICKSCAN™ STREP A SOFTWARE AS A MEDICAL DEVICE (SaMD)

Ethics Committee Approval Received for Pivotal Study Intended to Support U.S. FDA Class II Submission for QuickScan™ Strep AVANCOUVER, BC, June 4, 2026 /CNW/...

Parsons Accelerates Mission Success with Advanced AI

Key Takeaways:

EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus

BRUSSELS, Belgium and CAMBRIDGE, Mass., June 04, 2026 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Biogen Inc. (Nasdaq: BIIB) today announced data, comprising two posters and three abstracts, at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress, demonstrating the clinical profile of dapirolizumab pegol (DZP), an investigational biologic in patients with systemic lupus erythematosus (SLE).

Origin Energy and Landis+Gyr bring large-scale smart gas technology to Australian homes and businesses

The smart gas rollout will modernise customer and operational services without replacing existing infrastructure.SYDNEY, June 4, 2026 /PRNewswire/ -- Gas customers across Australia could...

Origin Energy and Landis+Gyr bring large-scale smart gas technology to Australian homes and businesses

The smart gas rollout will modernise customer and operational services without replacing existing infrastructure.SYDNEY, June 4, 2026 /PRNewswire/ -- Gas customers across Australia could...

Booking Health Announces Release of Findings on International Access to Personalized Glioblastoma Treatment in Germany

Langenfeld, Germany, June 03, 2026 (GLOBE NEWSWIRE) -- Booking Health today announced the release of findings examining international patient access to personalized dendritic cell therapy for glioblastoma in Germany. The findings, based on a documented Canadian patient case and supporting clinical research, highlight how cross-border treatment pathways may provide patients with aggressive brain tumors access to individualized immunotherapy options that are not widely available within all healthcare systems.

Digital University Unveils New LMS/SIS Capabilities

WASHINGTON, June 3, 2026 /PRNewswire/ -- Digital University (DU) is advancing its mission as the Department of War's (DoW) enterprise training and readiness platform by...

New Anglia University: Is Spending Six Years Abroad Still the Best Route Into Medicine?

New Anglia University examines changing medical education pathways, including international medical education and NHS clinical experience.

JJP Biologics Announces Positive Interim Phase 1b Data for Nebaprubart (JJP-1212), an Anti-CD89 Antagonist, in Linear IgA Disease (LAD)

Warsaw, Poland – June 03, 2026 – JJP Biologics, ("JJPBio" or the "Company") a clinical-stage, immune-focused biotech that engineers precision antibodies to correct derailed immune pathways that drive autoimmune diseases and cancer, today announces positive interim data from its ongoing Phase 1b trial evaluating nebaprubart, also known as JJP-1212, its investigational potential first-in-class anti-CD89 antagonist, in patients diagnosed with Linear IgA Disease (LAD), a rare autoantibody-mediated skin disease.

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Comments

This field is for validation purposes and should be left unchanged.

HomeTagsPathways

SEABOURN QUEST EMERGES FROM DRYDOCK WITH REIMAGINED SPACES AND A MORE REFINED ONBOARD EXPERIENCE

Allergy & Asthma Network Statement on Centers for Medicare & Medicaid Services Work Requirements Interim Final Rule

SOUTHERN READYMIX DRIVERS TO HOLD COMMUNITY ACTION

Tag: pathways

LanzaTech JV Successful IPO Underscores Strategic Value of More Secure Fuel Supply

HotSpot Therapeutics Presents Preclinical Data from Small Molecule IRF5 Inhibitor Program at EULAR 2026

LIGHT AI ANNOUNCES INITIATION OF FDA PIVOTAL CLINICAL TRIAL FOR QUICKSCAN™ STREP A SOFTWARE AS A MEDICAL DEVICE (SaMD)

Parsons Accelerates Mission Success with Advanced AI

EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus

Origin Energy and Landis+Gyr bring large-scale smart gas technology to Australian homes and businesses

Origin Energy and Landis+Gyr bring large-scale smart gas technology to Australian homes and businesses

Booking Health Announces Release of Findings on International Access to Personalized Glioblastoma Treatment in Germany

Digital University Unveils New LMS/SIS Capabilities

New Anglia University: Is Spending Six Years Abroad Still the Best Route Into Medicine?

JJP Biologics Announces Positive Interim Phase 1b Data for Nebaprubart (JJP-1212), an Anti-CD89 Antagonist, in Linear IgA Disease (LAD)

WIN EURASIA 2026 to Showcase the Future of Manufacturing

Young Explorers Invited to Discover Nature During Community BioBlitz at Muscle Shoals Reservation Trails

Lewis Cellars Announces $275,000 in Community Grants

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us